Items Tagged ‘car-t immunotherapy’

July 12th, 2017

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

By

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available  Positive ODAC recommendation is latest milestone for CTL019 program that started through collaboration […]

View full entry

Tags: car-t immunotherapy, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma